Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03037437 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT03037437 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 64 participants.
The verdict
NCT03037437, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
Interventions
- DRUG Sorafenib (SOR)
- DRUG Hydroxychloroquine (HCQ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2025-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03037437
The ClinicalTrials.gov registry entry for NCT03037437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib (SOR) is the first listed.
NCT03037437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03037437 about?
NCT03037437 is a clinical study titled "Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer". The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
What is the current status of trial NCT03037437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2017-02-16. Estimated completion is 2025-06-27.
What interventions are being tested in trial NCT03037437?
The interventions under investigation include: Sorafenib (SOR) (DRUG), Hydroxychloroquine (HCQ) (DRUG).
Who is sponsoring clinical trial NCT03037437?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.